MIM
CBIO

Monashee Investment Management’s Crescent Biopharma CBIO Stock Holding History

Monashee Investment Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,400
Closed -$175K – 178
2018
Q1 		$175K Buy
+1,400
New +$2.91M 0.05% 114
2017
Q3 		– Sell
-700
Closed -$781K – 98
2017
Q2 		$781K Buy
+700
New +$578K 0.33% 63

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Monashee Investment Management's CBIO Position: Q2 2018 in Review

Monashee Investment Management sold out of Crescent Biopharma (CBIO) in Q2 2018, closing a stake of 1,400 shares — an estimated $175K sold.

Monashee Investment Management first reported a position in CBIO in Q2 2017 and held it in 2 quarters. The position peaked at $781K in Q2 2017. 84 funds tracked by Wall St. Rank hold CBIO as of Q2 2018.

  • Monashee Investment Management reported no remaining Crescent Biopharma position as of Q2 2018 after selling out during the quarter.
  • Monashee Investment Management sold 1,400 Crescent Biopharma shares in Q2 2018, an estimated $175K.
  • Monashee Investment Management first reported a position in Crescent Biopharma in Q2 2017 and held it in 2 quarters.
  • Monashee Investment Management's Crescent Biopharma position peaked at $781K in Q2 2017.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2018.

Based on Monashee Investment Management's 13F filing for Q2 2018, filed 10 Aug 2018.